Table 1.

Characteristics of DAAs Approved by the European Medicines Agency (EMA).^a

Active substance (commercial name)	Year of approval	Dosage	Administration	Genotype
Sofosbuvir (Sovaldi)	2014	400 mg	12 wks (SOF + PegIFN/RBV)	1, 2, 3, and 4
			12 wks (SOF + RBV)
			24 wks (SOF + RBV)
			Until the transplantation 24 wks (SOF + RBV)
			Until the transplantation 48 wks (SOF + RBV)
			12 wks (SOF + SIM + RBV)
			24 wks (SOF + SIM + RBV)
Simeprevir (Olysio)	2015	150 mg	12 wks (SIM + PegIFN/RBV) + 12 wks (PegIFN/RBV)	1 and 4
			12 wks (SIM + PegIFN/RBV) + 36 wks (PegIFN/RBV)
			12 wks (SIM + SOF)
			12 wks (SIM + SOF) + 12 wks (SIM + SOF)
Daclatasvir (Daklinza)	2015	60 mg	12 wks (DACL + SOF ± RBV)	1, 3, and 4
			24 wks (DACL + SOF ± RBV)
			24 wks (DACL + PegIFN + RBV) + 24 wks (PegIFN/RBV)
Ledipasvir/sofosbuvir (Harvoni)	2014	90 mg/400 mg	8 wks (Led/SOF)	1,3, and 4
			12 wks (Led/SOF ± RBV)
			24 wks (Led/SOF ± RBV)
Ombitasvir/paritaprevir/ritonavir (Viekirax)	2015	12.5 mg/75 mg/250 mg	12 wks (ombitasvir/paritaprevir/ritonavir + RBV)	1 and 4
			24 wks (ombitasvir/paritaprevir/ritonavir + RBV)
Dasabuvir (Exviera)	2015	50 mg	12 wks (ombitasvir/paritaprevir/ritonavir + DAS)	1 and 4
			24 wks (ombitasvir/paritaprevir/ritonavir + DAS)
			12 wks (ombitasvir/paritaprevir/ritonavir + DAS + RBV)
			24 wks (ombitasvir/paritaprevir/ritonavir + DAS + RBV)
Grazoprevir/elbasvir (Zepatier)	2016	100 mg/50 mg	8 wks (GRA + ELB)	1 and 4
			12 wks (GRA + ELB ± RBV)
Velpatasvir/sofosbuvir (Epclusa)	2016	100 mg/400 mg	12 wks (Valp + SOF ± RBV)	1, 2, 3, 4, 5, and 6
Asunaprevir/daclatasvir/beclabuvir	Soon be available			1, 2, 3, 4, and 5

Wks, weeks; SOF, sofosbuvir; RBV, ribavirin; IFN, interferon; SIM, simeprevir; DACL, daclatasvir; Led, ledipasvir; DAS, dasabuvir; GRA, grazoprevir; ELB, elbasvir; Valp, velpatasvir.

^aFaldaprevir 120 mg was withdrawn during the marketing authorization procedure.